The equity lockup period for Bluebird Bio Inc. shares ends in a week following its $460.1 million stock sale.

Bluebird Bio sold 4.38 million shares at $105 on June 27. The sale increased the outstanding shares by 9.7 percent.
Since then, the stock has declined 9.5 percent and the benchmark Russell 2000 Health Care Index fell 1.1 percent. The S&P 500 Index climbed 2.4 percent in the same period.

The underwriters restricted sales by the company, directors and executives for 45 days. The agreement limits the sale of 344,300 shares, according to data compiled from prospectus documents. Those represent 1 percent of its market capitalization, 1 percent of its float and 0 days worth of average trading volume. The company has also set one other lockup date on Aug. 27.

Bluebird Bio rose 54.1 percent so far this year and advanced 64.4 percent in the past 52 weeks. The stock closed at $95.05 in the previous session. This story was produced by Bloomberg Automation

Eoin Treacy's view

This story, produced by a computer rather a reporter is an example of what we can expect from factual reporting in future. 

Bluebird has been among the better performing immuno-oncology shares this year. As the article above highlights the decline since June has priced in the dilution resulting from the recent share issue. The price is now back in the region of the trend mean and beginning to firm. A sustained move below Thursday’s low, near $85.65, would be required to question medium-term recovery potential.